Share on StockTwits
 

Investment analysts at Sanford C. Bernstein reduced their price target on shares of Sanofi-Aventis (NYSE:SNY) from $57.00 to $53.00 in a note issued to investors on Friday, American Banking News reports. Sanford C. Bernstein’s target price points to a potential upside of 9.44% from the company’s current price.

Sanofi-Aventis (NYSE:SNY) traded up 1.38% during mid-day trading on Friday, hitting $48.43. 4,794,330 shares of the company’s stock traded hands. Sanofi-Aventis has a 1-year low of $46.16 and a 1-year high of $55.94. The stock’s 50-day moving average is $50.69 and its 200-day moving average is $50.98. The company has a market cap of $128.4 billion and a price-to-earnings ratio of 31.41.

Sanofi-Aventis (NYSE:SNY) last released its earnings data on Thursday, February 6th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.05. On average, analysts predict that Sanofi-Aventis will post $3.42 earnings per share for the current fiscal year.

A number of other firms have also recently commented on SNY. Analysts at Citigroup Inc. downgraded shares of Sanofi-Aventis from a “buy” rating to a “neutral” rating in a research note to investors on Thursday, January 23rd. Separately, analysts at UBS AG initiated coverage on shares of Sanofi-Aventis in a research note to investors on Thursday, January 9th. They set a “neutral” rating on the stock. Finally, analysts at JPMorgan Chase & Co. downgraded shares of Sanofi-Aventis from an “overweight” rating to a “neutral” rating in a research note to investors on Monday, January 6th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $54.50.

Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.